JO3645B1 - أشكال جرعة دوائية تحتوي صوديوم 1-[6-(مورفولين-4- يل) بيريميدين-4- يل]-4-(1h-3،2،1- ترايازول-1- يل)-1h- بيرازول-5- ولات - Google Patents

أشكال جرعة دوائية تحتوي صوديوم 1-[6-(مورفولين-4- يل) بيريميدين-4- يل]-4-(1h-3،2،1- ترايازول-1- يل)-1h- بيرازول-5- ولات

Info

Publication number
JO3645B1
JO3645B1 JOP/2014/0295A JOP20140295A JO3645B1 JO 3645 B1 JO3645 B1 JO 3645B1 JO P20140295 A JOP20140295 A JO P20140295A JO 3645 B1 JO3645 B1 JO 3645B1
Authority
JO
Jordan
Prior art keywords
olate
morpholin
triazol
pyrazol
pyrimidin
Prior art date
Application number
JOP/2014/0295A
Other languages
English (en)
Inventor
Klaus Benke Dr
Gabriele Winter Dr
Heike Neumann Dr
Formell Michael
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49356354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3645(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of JO3645B1 publication Critical patent/JO3645B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الاختراع الحالي بأشكال جرعة دوائية صلبة للإعطاء المعوي تشمل sodium 1-[6-(morpholin-4-yl) pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (المقوم النشط (I))، تتميز بإطلاق المقوم النشط (I)، وأيضا بطرق لتحضيرها، واستخدامها كأدوية، وأيضا استخدامها من أجل الوقاية، الوقاية الثانوية أو علاج اضطرابات، خصوصا اضطرابات وعائية قلبية، فشل القلب، الأنيميا، الاضطرابات الكلوية المزمنة وعدم كفاءة الكلى.
JOP/2014/0295A 2013-10-17 2014-10-16 أشكال جرعة دوائية تحتوي صوديوم 1-[6-(مورفولين-4- يل) بيريميدين-4- يل]-4-(1h-3،2،1- ترايازول-1- يل)-1h- بيرازول-5- ولات JO3645B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13189145 2013-10-17

Publications (1)

Publication Number Publication Date
JO3645B1 true JO3645B1 (ar) 2020-08-27

Family

ID=49356354

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0295A JO3645B1 (ar) 2013-10-17 2014-10-16 أشكال جرعة دوائية تحتوي صوديوم 1-[6-(مورفولين-4- يل) بيريميدين-4- يل]-4-(1h-3،2،1- ترايازول-1- يل)-1h- بيرازول-5- ولات

Country Status (35)

Country Link
US (1) US9827198B2 (ar)
EP (1) EP3057580B1 (ar)
JP (1) JP6525979B2 (ar)
KR (1) KR102330953B1 (ar)
CN (1) CN105636580B (ar)
AP (1) AP2016009135A0 (ar)
AR (1) AR098064A1 (ar)
AU (1) AU2014336389B2 (ar)
BR (1) BR112016007588A2 (ar)
CA (1) CA2927437C (ar)
CL (1) CL2016000857A1 (ar)
CU (1) CU24515B1 (ar)
DK (1) DK3057580T3 (ar)
DO (1) DOP2016000078A (ar)
EA (1) EA032932B1 (ar)
ES (1) ES2868228T3 (ar)
GT (1) GT201600072A (ar)
HR (1) HRP20210691T1 (ar)
HU (1) HUE054107T2 (ar)
IL (1) IL244933B (ar)
JO (1) JO3645B1 (ar)
LT (1) LT3057580T (ar)
MA (1) MA38974B2 (ar)
MX (1) MX2016004628A (ar)
MY (1) MY190202A (ar)
NI (1) NI201600054A (ar)
PE (1) PE20160669A1 (ar)
PH (1) PH12016500716A1 (ar)
SA (1) SA516370940B1 (ar)
SI (1) SI3057580T1 (ar)
TN (1) TN2016000135A1 (ar)
TW (1) TWI746418B (ar)
UA (1) UA119855C2 (ar)
UY (1) UY35784A (ar)
WO (1) WO2015055564A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY199646A (en) * 2018-08-31 2023-11-14 Astellas Pharma Inc Pharmaceutical composition for oral administration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
BRPI0808889A2 (pt) * 2007-03-13 2014-11-11 Dainippon Sumitomo Pharma Co Comprimido desintegrante oral
DE102010044131A1 (de) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat

Also Published As

Publication number Publication date
AP2016009135A0 (en) 2016-04-30
AR098064A1 (es) 2016-04-27
CL2016000857A1 (es) 2016-11-25
EP3057580A1 (de) 2016-08-24
CA2927437A1 (en) 2015-04-23
PE20160669A1 (es) 2016-08-04
PH12016500716B1 (en) 2016-06-20
NZ718063A (en) 2021-06-25
SI3057580T1 (sl) 2021-07-30
MA38974B2 (fr) 2020-11-30
UY35784A (es) 2015-05-29
EA032932B1 (ru) 2019-08-30
BR112016007588A2 (pt) 2017-09-12
GT201600072A (es) 2018-12-19
MA38974A1 (fr) 2017-05-31
IL244933A0 (en) 2016-05-31
KR20160068784A (ko) 2016-06-15
AU2014336389A1 (en) 2016-05-12
JP2016538256A (ja) 2016-12-08
CU20160048A7 (es) 2016-10-28
EA201690788A1 (ru) 2016-09-30
DOP2016000078A (es) 2016-08-15
HRP20210691T1 (hr) 2021-06-11
US20160256394A1 (en) 2016-09-08
US9827198B2 (en) 2017-11-28
CU24515B1 (es) 2021-05-12
TN2016000135A1 (en) 2017-10-06
NI201600054A (es) 2016-09-21
SA516370940B1 (ar) 2019-11-20
UA119855C2 (uk) 2019-08-27
EP3057580B1 (de) 2021-02-24
TWI746418B (zh) 2021-11-21
LT3057580T (lt) 2021-04-12
JP6525979B2 (ja) 2019-06-05
DK3057580T3 (da) 2021-05-10
IL244933B (en) 2020-11-30
CN105636580B (zh) 2020-03-31
MY190202A (en) 2022-04-04
ES2868228T3 (es) 2021-10-21
KR102330953B1 (ko) 2021-11-26
HUE054107T2 (hu) 2021-08-30
WO2015055564A1 (de) 2015-04-23
CN105636580A (zh) 2016-06-01
AU2014336389B2 (en) 2020-01-30
PH12016500716A1 (en) 2016-06-20
TW201607568A (zh) 2016-03-01
MX2016004628A (es) 2016-08-01
CA2927437C (en) 2022-06-28

Similar Documents

Publication Publication Date Title
ZA202109164B (en) 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MA38399B2 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MY204827A (en) Semaglutide in medical therapy
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
PH12013500997A1 (en) Substituted sodium-1h-pyrazole-5-olate
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
JO3645B1 (ar) أشكال جرعة دوائية تحتوي صوديوم 1-[6-(مورفولين-4- يل) بيريميدين-4- يل]-4-(1h-3،2،1- ترايازول-1- يل)-1h- بيرازول-5- ولات
NZ708511A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну
SG10201809280PA (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
MX393290B (es) Composicion para el tratamiento de la osteoartritis
CR20160177A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)1h-pirazol-5-olato de sodio
NZ740690A (en) Treatment of alopecia areata